生物活性

• 描述Trelagliptin is a long acting dipeptidyl peptidase-4 (DPP-4) inhibitor that is being developed for the treatment of type 2 diabetes (T2D).
• 临床研究

• NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
  NCT01632007	Diabetes Mellitus	Phase 3	Completed	-	Japan ... more >> Akita-shi, Akita, Japan Matsudo-shi, Chiba, Japan Fukuoka-shi, Fukuoka, Japan Fukuyama-shi, Hiroshima, Japan Ishikari-shi, Hokkaido, Japan Nakagawa-gun, Hokkaido, Japan Sapporo-shi, Hokkaido, Japan Naka-shi, Ibaragi, Japan Sagamihara-shi, Kanagawa, Japan Kumamoto-shi, Kumamoto, Japan Kashiwara-shi, Osaka, Japan Osaka-shi, Osaka, Japan Suita-shi, Osaka, Japan Arakawa-ku, Tokyo, Japan Bunkyo-ku, Tokyo, Japan Chiyoda-ku, Tokyo, Japan Chuo-ku, Tokyo, Japan Itabashi-ku, Tokyo, Japan Katsushika-ku, Tokyo, Japan Mitaka-shi, Tokyo, Japan Shinjuku-ku, Tokyo, Japan Shunan-shi, Yamaguchi, Japan Collapse <<
  NCT02528019	Effects of the DPP-4 Inhibitor... more >>s or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications Collapse <<	Phase 4	Unknown	August 2018	Japan ... more >> Kurume University Hospital Recruiting Kurume city, Japan, 830-0011 Contact: Nobuhiro Tahara, MD, PhD    +81-942-31-7580    ntahara@med.kurume-u.ac.jp    Contact: Sho-ichi Yamagishi, MD, PhD    +81-942-31-7562       Principal Investigator: Nobuhiro Tahara, MD, PhD Collapse <<
  NCT00760344	Diabetes Mellitus	Phase 2	Completed	-	-

• 更多
• 参考文献

• [1] Kaku K. First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother. 2015;16(16):2539-47.

  [2] Inagaki N, Onouchi H, et al. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 Feb;2(2):125-32.